Grimm M, Cetindis M, Biegner T, Lehman M, Munz A, Teriete P, Reinert S. Serum vitamin D levels of patients
with oral squamous cell carcinoma (OSCC) and
expression of vitamin D receptor in oral precancerous lesions and OSCC. Med Oral Patol
Oral Cir Bucal. 2015 Mar 1;20
(2):e188-95.
doi:10.4317/medoral.20368
http://dx.doi.org/doi:10.4317/medoral.20368
|
1. Choudhari
SK, Chaudhary M, Gadbail
AR, Sharma A, Tekade S. Oxidative and antioxidative mechanisms in oral cancer and precancer: a review. Oral Oncol.
2014;50:10-8. |
|
|
|
|
|
2. Tanaka T, Tanaka M, Tanaka T.
Oral carcinogenesis and oral cancer chemoprevention: a review. Patholog Res Int. 2011;2011:431246. |
|
|
|
|
|
3. Driemel
O, Hertel K, Reichert TE, Kosmehl
H. Current classification of precursor lesions of oral squamous
cell carcinoma principles of the WHO classification 2005. Mund
Kiefer Gesichtschir. 2006;10:89-93. |
|
|
|
|
|
4. Grimm M. Prognostic value of clinicopathological parameters and outcome in 484
patients with oral squamous cell carcinoma: microvascular invasion (V+) is an independent prognostic
factor for OSCC. Clinical & translational oncology :
official publication of the Federation of Spanish Oncology Societies and of
the National Cancer Institute of Mexico. 2012;14:870-80. |
|
|
|
|
|
5. Perez-Sayans
M, Suarez-Penaranda JM, Pilar GD, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A. Hypoxia-inducible
factors in OSCC. Cancer letters. 2011;313:1-8. |
|
|
|
|
|
6. Ouyang
L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death
pathways in cancer: a review of apoptosis, autophagy
and programmed necrosis. Cell Prolif.
2012;45:487-98. |
|
|
|
|
|
7. Sinha
N, Mukhopadhyay S, Das DN, Panda PK, Bhutia SK. Relevance of cancer initiating/stem cells in
carcinogenesis and therapy resistance in oral cancer. Oral Oncol. 2013;49:854-62. |
|
|
|
|
|
8. Grimm M, Schmitt S, Teriete P, Biegner T, Stenzl A, Hennenlotter J, et
al. A biomarker based detection and characterization of carcinomas exploiting
two fundamental biophysical mechanisms in mammalian cells. BMC Cancer. 2013;13:569. |
|
|
|
|
|
9. Richard V, Sebastian P, Nair
MG, Nair SN, Malieckal TT, Santhosh
Kumar TR, et al. Multiple drug resistant, tumorigenic
stem-like cells in oral cancer. Cancer Lett. 2013;338:300-16. |
|
|
|
|
|
10. Nair R, Maseeh
A. Vitamin D: The "sunshine" vitamin. J Pharmacol
Pharmacother. 2012;3:118-26. |
|
|
|
|
|
11. Grimm M, Alexander D, Munz A, Hoffmann J, Reinert S.
Is 1,25-dihydroxyvitamin D3 receptor expression a potential Achilles' heel of
CD44+ oral squamous cell carcinoma cells?. Target Oncol. 2013;8:189-201. |
|
|
|
|
|
12. Kornfehl
J, Formanek M, Temmel A, Knerer B, Willheim M. Antiproliferative effects of the biologically active metabolite of vitamin D3 (1,25
[OH]2 D3) on head and neck
squamous cell carcinoma cell lines. European
archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological
Societies. 1996;253:341-4. |
|
|
|
|
|
13. Kulbersh
JS, Day TA, Gillespie MB,
Young MR. 1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral
levels of immune inhibitory CD34(+) progenitor cells
into dendritic cells. Otolaryngology--head and
neck surgery: official journal of American Academy of Otolaryngology-Head
and Neck Surgery. 2009;140:235-40. |
|
|
|
|
|
14. Young MR, Wright MA, Lozano Y,
Prechel MM, Benefield J, Leonetti JP, et al. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage
colony-stimulating factor and contained
CD34+ natural suppressor cells.
Int J Cancer. 1997;74:69-74. |
|
|
|
|
|
15. Lu L, Qiu
J, Liu S, Luo W. Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Molecular cancer therapeutics. 2008;7:1268-74. |
|
|
|
|
|
16. Hager
G, Kornfehl J, Knerer B, Weigel G, Formanek M. Molecular
analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence
of 1,25(OH)2 vitamin D3 and its
analogs. Acta oto-laryngologica.
2004;124:90-6. |
|
|
|
|
|
17. Satake
K, Takagi E, Ishii A, Kato Y, Imagawa Y, Kimura Y, et al. Anti-tumor effect
of vitamin A and D on
head and neck squamous cell carcinoma. Auris Nasus Larynx. 2003;30:403-12. |
|
|
|
|
|
18. Prudencio J, Akutsu N, Benlimame N, Wang T, Bastien Y, Lin R, et al. Action of low calcemic 1alpha,25-dihydroxyvitamin
D3 analogue EB1089 in head and neck
squamous cell carcinoma. Journal of the National Cancer Institute. 2001;93:745-53. |
|
|
|
|
|
19. Meier
JD, Enepekides DJ, Poirier B, Bradley CA, Albala JS, Farwell DG. Treatment with 1-alpha,25-dihydroxyvitamin D3 (vitamin
D3) to inhibit carcinogenesis in the hamster buccal pouch model. Archives of otolaryngology--head & neck
surgery. 2007;133:1149-52. |
|
|
|
|
|
20. Osafi
J, Hejazi A, Stutz DD, Keiserman MA, Bergman CJ, Kingsley
K. Differential effects
of 1,25-dihydroxyvitamin D(3) on
oral squamous cell carcinomas
in vitro. J Diet Suppl.
2014;11:145-54. |
|
|
|
|
|
21. Dalirsani
Z, Farajnia S, Javadzadeh
Y, Mehdipour M, Koozegari
S. The effects of
5-fluorouracil alone and in combination
with 13-cis retinoic acid and vitamin D3 on human oral squamous cell carcinoma lines. J Contemp Dent Pract. 2012;13:345-50. |
|
|
|
|
|
22. Tuohimaa
P, Lou YR. Optimal serum calcidiol concentration for cancer prevention.
Anticancer Res. 2012;32:373-81. |
|
|
|
|
|
23. Zerwekh
JE. Blood biomarkers of vitamin D status. Am J Clin Nutr. 2008;87:1087S-91S. |
|
|
|
|
|
24. Walker RA. Quantification
of immunohistochemistry--issues
concerning methods, utility and semiquantitative assessment I. Histopathology. 2006;49:406-10. |
|
|
|
|
|
25. Alipour
S, Hadji M, Hosseini L, Omranipour R, Saberi A, Seifollahi A, et al. Levels of serum 25-hydroxy-vitamin d in benign
and malignant breast masses. Asian Pac J Cancer Prev. 2014;15:129-32. |
|
|
|
|
|
26. Visvader
JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer.
2008;8:755-68. |
|
|
|
|
|
27. Nowell
PC. The clonal evolution of tumor cell populations. Science. 1976;194:23-8. |
|
|
|
|
|
28. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or
clonal evolution? Cell Cycle. 2007;6:2332-8. |
|
|
|
|
|
29. Bonnet D, Dick
JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med.
1997;3:730-7. |
|
|
|
|
|
30. Reya T, Clevers
H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843-50. |
|
|
|
|
|
31. So JY, Lee HJ, Smolarek AK, Paul S, Wang CX, Maehr
H, et al. A novel Gemini vitamin
D analog represses the expression of a stem cell marker
CD44 in breast cancer. Mol
Pharmacol. 2011;79:360-7. |
|
|
|
|
|
32. Pervin
S, Hewison M, Braga M, Tran
L, Chun R, Karam A, et
al. Down-regulation of vitamin
D receptor in mammospheres: implications
for vitamin D resistance in breast cancer and potential for combination therapy. PLoS One. 2013;8:e53287. |
|
|
|
|
|
33. Souza RF, Krishnan
K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol. 2008;295:G211-8. |
|
|
|
|
|
34. Jeon
J, Luebeck EG, Moolgavkar
SH. Age effects and
temporal trends in adenocarcinoma
of the esophagus and gastric cardia (United States). Cancer Causes Control. 2006;17:971-81. |
|
|
|
|
|
35. von Rahden
BH, Kircher S, Lazariotou
M, Reiber C, Stuermer L,
Otto C, et al. LgR5 expression and cancer stem cell
hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's Esophagus? J Exp Clin Cancer Res. 2011;30:23. |
|
|
|
|
|
36. Gimenez-Bonafe
P, Tortosa A, Perez-Tomas R. Overcoming
drug resistance by enhancing apoptosis of tumor
cells. Curr Cancer Drug Targets. 2009;9:320-40. |
|
|
|
|
|
37. Sundaram
K, Sambandam Y, Tsuruga
E, Wagner CL, Reddy SV. 1alpha,25-dihydroxyvitamin
D3 modulates CYP2R1 gene expression
in human oral squamous cell carcinoma tumor cells. Horm Cancer. 2014;5:90-7. |
|
|
|
|
|
38. Guyton
KZ, Kensler TW, Posner
GH. Cancer chemoprevention
using natural vitamin D
and synthetic analogs. Annu Rev Pharmacol
Toxicol. 2001;41:421-42. |
|
|
|
|
|
39. Tretli
S, Schwartz GG, Torjesen
PA, Robsahm TE. Serum levels of 25-hydroxyvitamin D and survival
in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control.
2012;23:363-70. |
|
|
|
|
|
40. Anderson LN, Cotterchio M, Vieth R, Knight JA. Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal
women. Am J Clin Nutr. 2010;91:1699-707. |
|
|
|
|
|
41. Heaney
RP. Vitamin D in health
and disease. Clin J Am Soc Nephrol. 2008;3:1535-41. |
|
|
|
|
|
42. Anand
S, Rollakanti KR, Horst RL, Hasan T, Maytin EV. Combination of oral vitamin D3 with photodynamic therapy enhances tumor cell death in a murine model of cutaneous squamous cell carcinoma. Photochem Photobiol. 2014;90:1126-35. |
|
|
|
|
|
43. Slaughter
DP, Southwick HW, Smejkal
W. Field cancerization in
oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6:963-8. |
|
|
|
|
|
44. Angadi
PV, Savitha JK, Rao SS, Sivaranjini Y. Oral field cancerization: current evidence and future perspectives. Oral Maxillofac Surg. 2012;16:171-80. |
|
|
|
|
|
45. Leon
X, del Prado Venegas M, Orus C, Lopez
M, Garcia J, Quer M. Influence of the persistence of tobacco and
alcohol use in the appearance
of second neoplasm in patients with a head and neck cancer. A case-control study. Cancer Causes Control.
2009;20:645-52. |
|
|
|
|
|
46. Malodobra-Mazur
M, Paduch A, Lebioda A, Konopacka M, Rogolinski J, Szymczyk C, et al. VDR gene single nucleotide
polymorphisms and their association with risk of oral cavity carcinoma. Acta
Biochim Pol. 2012;59:627-30. |
|
|
|
|
|
47. Costa EM, Feldman
D. Measurement of 1,25-dihydroxyvitamin D3 receptor
turnover by dense amino acid labeling: changes during receptor up-regulation by vitamin D metabolites. Endocrinology. 1987;120:1173-8. |
|
|
|
|
|
48. Wiese
RJ, Uhland-Smith A, Ross TK, Prahl JM, DeLuca HF. Up-regulation of the vitamin D receptor in
response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. The Journal of biological chemistry. 1992;267:20082-6. |
|
|
|
|
|
49. Mangelsdorf
DJ, Pike JW, Haussler MR. Avian
and mammalian receptors for 1,25-dihydroxyvitamin D3: in vitro translation to characterize size and hormone-dependent regulation. Proceedings of the National Academy of Sciences of the United States of America. 1987;84:354-8. |
|
|
|
|
|
50. Lehmann
B. HaCaT cell line as a model system for vitamin D3 metabolism in human skin. The Journal
of investigative dermatology.
1997;108:78-82. |
|
|
|
|
|
51. Reichrath
J, Rafi L, Muller SM, Mink D, Reitnauer K, Tilgen W, et al. Immunohistochemical
analysis of 1,25-dihydroxyvitamin D3 receptor in cervical
carcinoma. Histochem J. 1998;30:561-7. |
|
|
|
|
|
52. Gugatschka
M, Kiesler K, Obermayer-Pietsch
B, Groselj-Strele A, Griesbacher
A, Friedrich G. Vitamin D
status is associated with disease-free survival and overall survival time in patients with squamous cell carcinoma of the upper aerodigestive tract. Eur Arch
Otorhinolaryngol. 2011;268:1201-4. |
|
|
|
|
|
53. Pludowski
P, Grant WB, Bhattoa HP,
Bayer M, Povoroznyuk V, Rudenka
E, et al. Vitamin D Status in Central Europe. Int J Endocrinol. 2014;2014:589587. |
|
|
|
|
|
54. Arem
H, Weinstein SJ, Horst RL, Virtamo
J, Yu K, Albanes D, et al. Serum
25-hydroxyvitamin D and risk of oropharynx
and larynx cancers in Finnish men. Cancer Epidemiol Biomarkers Prev. 2011;20:1178-84. |
|
|
|
|
|
55. Yuan FN, Valiyaparambil
J, Woods MC, Tran H, Pant
R, Adams JS, et al. Vitamin D signaling
regulates oral keratinocyte
proliferation in vitro and in vivo. Int J Oncol. 2014;44:1625-33. |
|
|
|
|
|
56. Afzal
S, Bojesen SE, Nordestgaard
BG. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem. 2013;59:771-80. |
|